Treatment recommendations for metastatic colorectal cancer

Clinical and Translational Oncology

Volumn 13, Issue 3, 2011, Pages 162-178

  Aranda, Enrique ^a   Abad, Albert ^b   Carrato, Alfredo ^c   Cervantes, Andrés ^d   García Foncillas, Jesús ^e   García Alfonso, Pilar ^f   García Carbonero, Rocío ^g   Gómez España, Auxiliadora ^a   Tabernero, Josep M ^h   Díaz Rubio, Eduardo ⁱ  

^a HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^b HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^c HOSPITAL RAMÓN Y CAJAL   (Spain)

^d HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^e Clinica Universidadde Navarra   (Spain)

^f HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^g HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^h HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

ⁱ HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

Chemotherapy; Metastatic colorectal cancer

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; BEVACIZUMAB; BIOLOGICAL MARKER; CAPECITABINE; CETUXIMAB; DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; GLUCURONOSYLTRANSFERASE 1A1; IRINOTECAN; K RAS PROTEIN; MONOCLONAL ANTIBODY; OXALIPLATIN; PANITUMUMAB; PLACEBO; VASCULOTROPIN ANTIBODY;

ABDOMINAL PAIN; ACNE; ADVANCED CANCER; ASTHENIA; BRONCHOSPASM; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CARCINOMATOUS PERITONITIS; CHEMOTHERAPY INDUCED EMESIS; CLINICAL EVALUATION; CLINICAL FEATURE; CLINICAL PRACTICE; COLON RESECTION; COLORECTAL CANCER; CONJUNCTIVITIS; CONTINUOUS INFUSION; CYTOREDUCTIVE SURGERY; DIARRHEA; DNA POLYMORPHISM; DRUG EFFECT; DRUG HALF LIFE; DRUG HYDROLYSIS; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; DRY SKIN; ECHOGRAPHY; FATTY LIVER; GRANULOCYTOPENIA; HUMAN; HYPERTHERMIC THERAPY; HYPOMAGNESEMIA; INTERMETHOD COMPARISON; INTERSTITIAL PNEUMONIA; INTESTINE PERFORATION; LABORATORY TEST; LIVER METASTASIS; LIVER TOXICITY; LUNG EDEMA; LUNG METASTASIS; LYMPH NODE METASTASIS; METASTASIS; METASTASIS RESECTION; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PARONYCHIA; PERIPHERAL NEUROPATHY; PHARMACOGENETICS; PRACTICE GUIDELINE; PREDICTION; PRURITUS; RADIOFREQUENCY ABLATION; REVIEW; SKIN TOXICITY; SPIRAL COMPUTER ASSISTED TOMOGRAPHY; THORAX RADIOGRAPHY; TREATMENT PLANNING; UNSPECIFIED SIDE EFFECT;

COLORECTAL NEOPLASMS; HUMANS; NEOPLASM METASTASIS; NEOPLASM STAGING; PRACTICE GUIDELINES AS TOPIC;

EID: 79958228225     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-011-0636-7     Document Type: Review

References (190)

1. Bosetti C, Bertuccio P, Levi F et al (2008) Cancer mortality in the European Union, 1970-2003, with a joinpoint analysis. Ann Oncol 19:631-640
2. Jemal A, Siegel R, Ward E et al (2007) Cancer statistics, 2007. CA Cancer J Clin 57:43-66 (Pubitemid 46148091)
3. Ferlay J, Autier P, Boniol M et al (2007) Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 18:581-592
4. Verdecchia A, Francisci S, Brenner H et al (2007) Recent cancer survival in Europe: a 2000-02 period analysis of EUROCARE-4 data. Lancet Oncol 8:784-796 (Pubitemid 47321601)
5. Área de epidemiología ambiental y Cáncer, Centro Nacional de Epidemiología, Instituto de Salud Carlos III (2007) Mortalidad por cáncer y otras causasen España, año 2005. http://www.isciii.es/htdocs/pdf/mort2005-.pdf. April 1 [cited 2008]
6. Khatri VP, Petrelli NJ, Belghiti J (2005) Extending the frontiers of surgical therapy for hepatic colorectal metastases: is there a limit? J Clin Oncol 23:8490-8499
7. Van Cutsem E, Nordlinger B, Adam R et al (2006) Towards a pan-European consensus on the treatment of patients with colorectal liver metastases. Eur J Cancer 42:2212-2221 (Pubitemid 44307626)
8. Yoo PS, Lopez-Soler RI, Longo WE, Cha CH (2006) Liver resection for metastatic colorectal cancer in the age of neoadjuvant chemotherapy and bevacizumab. Clin Colorectal Cancer 6:202-207 (Pubitemid 44596769)
9. Alberts SR, Horvath WL, Sternfeld WC et al (2005) Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. J Clin Oncol 23:9243-9249
10. Kemeny N (2006) Management of liver metastases from colorectal cancer. Oncology (Williston Park) 20:1161-1176, 1179
11. Muratore A, Zorzi D, Bouzari H et al (2007) Asymptomatic colorectal cancer with un-resectable liver metastases: immediate colorectal resection or up-front systemic chemotherapy? Ann Surg Oncol 14:766-770
12. Bipat S, van Leeuwen MS, Comans EF et al (2005) Colorectal liver metastases: CT, MR imaging, and PET for diagnosis - meta-analysis. Radiology 237:123-131
13. Rappeport ED, Loft A, Berthelsen AK et al (2007) Contrast-enhanced FDG-PET/CT vs. SPIO-enhanced MRI vs. FDG-PET vs. CT in patients with liver metastases from colorectal cancer: a prospective study with intraoperative confirmation. Acta Radiol 48:369-378
14. Huebner RH, Park KC, Shepherd JE et al (2000) A meta-analysis of the literature for whole-body FDG PET detection of recurrent colorectal cancer. J Nucl Med 41:1177-1189 (Pubitemid 30464000)
15. Köhne CH, Cunningham D, Di CF et al (2002) Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. Ann Oncol 13:308-317
16. De Roock W, Piessevaux H, De Schutter J et al (2008) KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol 19:508-515 (Pubitemid 351325672)
17. Di Fiore F, Blanchard F, Charbonnier F et al (2007) Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by cetuximab plus chemotherapy. Br J Cancer 96:1166-1169 (Pubitemid 46625066)
18. Lievre A, Bachet JB, Le CD et al (2006) KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 66:3992-3995
19. Lievre A, Bachet JB, Boige V et al (2008) KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 26:374-379 (Pubitemid 351171687)
20. Van Cutsem E, Kohne CH, Hitre E et al (2009) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360:1408-1417
21. Bokemeyer C, Bondarenko I, Makhson A et al (2009) Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 27:663-671
22. Douillard JY, Siena S, Cassidy J et al (2010) Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 28:4697-4705
23. Laurent-Puig P, Cayre A, Manceau G et al (2009) Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol 27:5924-5930
24. Tol J, Nagtegaal ID, Punt CJ (2009) BRAF mutation in metastatic colorectal cancer. N Engl J Med 361:98-99
25. Loupakis F, Pollina L, Stasi I et al (2009) PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. J Clin Oncol 27:2622-2629
26. Sartore-Bianchi A, Di Nicolantonio F, Nichelatti M et al (2009) Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer. PLoS One 4:e7287
27. Loupakis F, Ruzzo A, Cremolini C et al (2009) KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. Br J Cancer 101:715-721
28. Amado RG, Wolf M, Peeters M et al (2008) Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26:1626-1634
29. Cote JF, Kirzin S, Kramar A et al (2007) UGT1A1 polymorphism can predict hematologic toxicity in patients treated with irinotecan. Clin Cancer Res 13:3269-3275 (Pubitemid 46944912)
30. Hoskins JM, Goldberg RM, Qu P et al (2007) UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters. J Natl Cancer Inst 99:1290-1295 (Pubitemid 47394168)
31. Innocenti F, Undevia SD, Iyer L et al (2004) Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 22:1382-1388 (Pubitemid 41103619)
32. Massacesi C, Terrazzino S, Marcucci F et al (2006) Uridine diphosphate glucuronosyl transferase 1A1 promoter polymorphism predicts the risk of gastrointestinal toxicity and fatigue induced by irinotecan-based chemotherapy. Cancer 106:1007-1016
33. Stewart CF, Panetta JC, O'Shaughnessy MA et al (2007) UGT1A1 promoter genotype correlates with SN-38 pharmacokinetics, but not severe toxicity in patients receiving low-dose irinotecan. J Clin Oncol 25:2594-2600 (Pubitemid 47041233)
34. Toffoli G, Cecchin E, Corona G et al (2006) The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer. J Clin Oncol 24:3061-3068 (Pubitemid 46638941)
35. Zhang X, Diasio RB (2007) Regulation of human dihydropyrimidine dehydrogenase: implications in the pharmacogenetics of 5-FU-based chemotherapy. Pharmacogenomics 8:257-265 (Pubitemid 46477736)
36. Yen JL, McLeod HL (2007) Should DPD analysis be required prior to prescribing fluoropyrimidines? Eur J Cancer 43:1011-1016
37. Zhu AX, Puchalski TA, Stanton VP Jr et al (2004) Dihydropyrimidine dehydrogenase and thymidylate synthase polymorphisms and their association with 5-fluorouracil/leucovorin chemotherapy in colorectal cancer. Clin Colorectal Cancer 3:225-234 (Pubitemid 38444309)
38. Cohen SJ, Alpaugh RK, Gross S et al (2006) Isolation and characterization of circulating tumor cells in patients with metastatic colorectal cancer. Clin Colorectal Cancer 6:125-132 (Pubitemid 44445747)
39. Sastre J, Maestro ML, Puente J et al (2008) Circulating tumor cells in colorectal cancer: correlation with clinical and pathological variables. Ann Oncol 19:935-938 (Pubitemid 351627310)
40. Meropol NJ, Cohen SJ, Iannotti N et al (2007) Circulating tumor cells (CTC) predict progression free (PFS) and overall survival (OS) in patients with metastatic colorectal cancer. J Clin Oncol 25:4010
41. Libra M, Navolanic PM, Talamini R et al (2004) Thymidylate synthetase mRNA levels are increased in liver metastases of colorectal cancer patients resistant to fluoropyrimidine-based chemotherapy. BMC Cancer 4:11
42. Ricciardiello L, Ceccarelli C, Angiolini G et al (2005) High thymidylate synthase expression in colorectal cancer with microsatellite instability: implications for chemotherapeutic strategies. Clin Cancer Res 11:4234-4240 (Pubitemid 40791590)
43. DiPaolo A, Chu E (2004) The role of thymidylate synthase as a molecular biomarker. Clin Cancer Res 10:411-412 (Pubitemid 38173975)
44. Salgado J, Zabalegui N, Gil C et al (2007) Polymorphisms in the thymidylate synthase and dihydropyrimidine dehydrogenase genes predict response and toxicity to capecitabine-raltitrexed in colorectal cancer. Oncol Rep 17:325-328
45. Rahman L, Voeller D, Rahman M et al (2004) Thymidylate synthase as an oncogene: a novel role for an essential DNA synthesis enzyme. Cancer Cell 5:341-351 (Pubitemid 38482070)
46. Marcuello E, Altés A, del Rio E et al (2004) Single nucleotide polymorphism in the 5' tandem repeat sequences of thymidylate synthase gene predicts for response to fluorouracil-based chemotherapy in advanced colorectal cancer patients. Int J Cancer 112:733-737 (Pubitemid 39435256)
47. Martinez-Balibrea E, Manzano JL, Martinez-Cardus A et al (2007) Combined analysis of genetic polymorphisms in thymidylate synthase, uridine diphosphate glucoronosyltransferase and X-ray cross complementing factor 1 genes as a prognostic factor in advanced colorectal cancer patients treated with 5-fluorouracil plus oxaliplatin or irinotecan. Oncol Rep 17:637-645
48. Lecomte T, Ferraz JM, Zinzindohoue F et al (2004) Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy. Clin Cancer Res 10:5880-5888 (Pubitemid 39180969)
49. Popat S, Matakidou A, Houlston RS (2004) Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and metaanalysis. J Clin Oncol 22:529-536 (Pubitemid 41079782)
50. Stoehlmacher J, Park DJ, Zhang W et al (2004) A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer. Br J Cancer 91:344-354 (Pubitemid 39037082)
51. Stoehlmacher J, Ghaderi V, Iobal S et al (2001) A polymorphism of the XRCC1 gene predicts for response to platinum based treatment in advanced colorectal cancer. Anticancer Res 21:3075-3079 (Pubitemid 33051178)
52. Ince WL, Jubb AM, Holden SN et al (2005) Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab. J Natl Cancer Inst 97:981-989 (Pubitemid 41430564)
53. Calvani M, Trisciuoglio D, Bergamaschi C et al (2008) Differential involvement of vascular endothelial growth factor in the survival of hypoxic colon cancer cells. Cancer Res 68:285-291 (Pubitemid 351380130)
54. Damiano V, Caputo R, Garofalo S et al (2007) TLR9 agonist acts by different mechanisms synergizing with bevacizumab in sensitive and cetuximab-resistant colon cancer xenografts. Proc Natl Acad Sci U S A 104:12468-12473 (Pubitemid 47206161)
55. Logan-Collins JM, Lowy AM, Robinson-Smith TM et al (2008) VEGF expression predicts survival in patients with peritoneal surface metastases from mucinous adenocarcinoma of the appendix and colon. Ann Surg Oncol 15:738-744
56. Varey AH, Rennel ES, Qiu Y et al (2008) VEGF 165 b, an antiangiogenic VEGF-A isoform, binds and inhibits bevacizumab treatment in experimental colorectal carcinoma: balance of pro- and antiangiogenic VEGF-A isoforms has implications for therapy. Br J Cancer 98:1366-1379 (Pubitemid 351543576)
57. Chun YS, Vauthey JN, Boonsirikamchai P et al (2009) Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases. JAMA 302:2338-2344
58. Kopetz S, Hoff PM, Morris JS et al (2010) Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J Clin Oncol 28:453-459
59. Gayowski TJ, Iwatsuki S, Madariaga JR et al (1994) Experience in hepatic resection for metastatic colorectal cancer: analysis of clinical and pathologic risk factors. Surgery 116:703-710
60. Nordlinger B, Guiguet M, Vaillant JC et al (1996) Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Francaise de Chirurgie. Cancer 77:1254-1262
61. Fong Y, Fortner J, Sun RL et al (1999) Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 230:309-318
62. Iwatsuki S, Dvorchik I, Madariaga JR et al (1999) Hepatic resection for metastatic colorectal adenocarcinoma: a proposal of a prognostic scoring system. J Am Coll Surg 189:291-299 (Pubitemid 29408866)
63. Figueras J, Valls C, Rafecas A et al (2001) Resection rate and effect of postoperative chemotherapy on survival after surgery for colorectal liver metastases. Br J Surg 88:980-985 (Pubitemid 34015581)
64. Tomlinson JS, Jarnagin WR, DeMatteo RP et al (2007) Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol 25:4575-4580 (Pubitemid 350035315)
65. Cummings LC, Payes JD, Cooper GS (2007) Survival after hepatic resection in metastatic colorectal cancer: a population-based study. Cancer 109:718-726 (Pubitemid 46233233)
66. National Comprehensive Cancer Network (NCCN) (2007) NCCN practice guidelines in oncology. V.2. www.nccn.org
67. Portier G, Elias D, Bouche O et al (2006) Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial. J Clin Oncol 24:4976-4982 (Pubitemid 46631399)
68. Nordlinger B, Sorbye H, Glimelius B et al (2008) Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 371:1007-1016 (Pubitemid 351392040)
69. Adam R, Avisar E, Ariche A et al (2001) Fiveyear survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal. Ann Surg Oncol 8:347-353 (Pubitemid 32422861)
70. Bismuth H, Adam R, Levi F et al (1996) Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg 224:509-520
71. Giacchetti S, Itzhaki M, Gruia G et al (1999) Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann Oncol 10:663-669 (Pubitemid 29342371)
72. Adam R, Pascal G, Castaing D et al (2004) Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases? Ann Surg 240:1052-1061
73. Tabernero J, Van Cutsem E, Díaz-Rubio E et al (2007) Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 25:5225-5232 (Pubitemid 350232254)
74. Min BS, Kim NK, Ahn JB et al (2007) Cetuximab in combination with 5-fluorouracil, leucovorin and irinotecan as a neoadjuvant chemotherapy in patients with initially unresectable colorectal liver metastases. Onkologie 30:637-643 (Pubitemid 350247762)
75. Ellis LM, Curley SA, Grothey A (2005) Surgical resection after downsizing of colorectal liver metastasis in the era of bevacizumab. J Clin Oncol 23:4853-4855 (Pubitemid 46223989)
76. Gruenberger B, Tamandl D, Schueller J et al (2008) Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. J Clin Oncol 26:1830-1835
77. Ribero D, Wang H, Donadon M et al (2007) Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases. Cancer 110:2761-2767
78. Reddy SK, Morse MA, Hurwitz HI et al (2008) Addition of bevacizumab to irinotecan- and oxaliplatin- based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases. J Am Coll Surg 206:96-106 (Pubitemid 350267242)
79. Abad A, Massuti B, Anton A et al (2008) Colorectal cancer metastasis resectability after treatment with the combination of oxaliplatin, irinotecan and 5-fluorouracil. Final results of a phase II study. Acta Oncol 47:286-292
80. Falcone A, Ricci S, Brunetti I et al (2007) Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 25:1670-1676 (Pubitemid 46797946)
81. Folprecht G, Gruenberger T, Bechstein WO et al (2010) Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol 11:38-47
82. Folprecht G, Grothey A, Alberts S et al (2005) Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol 16:1311-1319 (Pubitemid 41158476)
83. Vauthey JN, Pawlik TM, Ribero D et al (2006) Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 24:2065-2072 (Pubitemid 46622116)
84. Benoist S, Brouquet A, Penna C et al (2006) Complete response of colorectal liver metastases after chemotherapy: does it mean cure? J Clin Oncol 24:3939-3945 (Pubitemid 46630742)
85. Abdalla EK, Vauthey JN, Ellis LM et al (2004) Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg 239:818-825
86. Goldberg RM, Köhne CH, Seymour MT et al (2007) A pooled safety and efficacy analysis examining the effect on performance status (PS) on outcomes in nine first-line treatment (rx) trials (cts) of 6,286 patients (pts) with metastatic colorectal cancer (MCRC). J Clin Oncol 25:4011
87. Grothey A, Sargent D, Goldberg RM, Schmoll HJ (2004) Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 22:1209-1214 (Pubitemid 41079833)
88. Seymour MT, Maughan TS, Ledermann JA et al (2007) Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet 370:143-152 (Pubitemid 47042894)
89. Koopman M, Antonini NF, Douma J et al (2007) Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. Lancet 370:135-142 (Pubitemid 47042893)
90. Tournigand C, Andre T, Achille E et al (2004) FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22:229-237 (Pubitemid 41095086)
91. Maughan T, Adams RA, Smith CG et al (2009) 6LBA Addition of cetuximab to oxaliplatin-based combination chemotherapy (CT) in patients with KRAS wild-type advanced colorectal cancer (ACRC): a randomised superiority trial (MRC COIN). Eur J Cancer 7:4-5
92. Seymour MT, Maughan TS, Wasan HS et al (2007) Capecitabine (Cap) and oxaliplatin (Ox) in elderly and/or frail patients with metastatic colorectal cancer: the FOCUS2 trial. J Clin Oncol 25:9030
93. Goldberg RM, Rothenberg ML, Van Cutsem E et al (2007) The continuum of care: a paradigm for the management of metastatic colorectal cancer. Oncologist 12:38-50 (Pubitemid 46143501)
94. Abad A, Carrato A, Navarro M et al (2005) Two consecutive phase II trials of biweekly oxaliplatin plus weekly 48-hour continuous infusion of nonmodulated high-dose 5-fluorouracil as first-line treatment for advanced colorectal cancer. Clin Colorectal Cancer 4:384-389 (Pubitemid 41268775)
95. Aranda E, Diaz-Rubio E, Cervantes A et al (1998) Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with weekly high-dose 48-hour continuous-infusion fluorouracil for advanced colorectal cancer: a Spanish Cooperative Group for Gastrointestinal Tumor Therapy (TTD) study. Ann Oncol 9:727-731 (Pubitemid 28394158)
96. Colucci G, Gebbia V, Paoletti G et al (2005) Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. J Clin Oncol 23:4866-4875 (Pubitemid 46223991)
97. de Gramont A, Figer A, Seymour M et al (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18:2938-2947 (Pubitemid 30644117)
98. Goldberg RM, Sargent DJ, Morton RF et al (2004) A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22:23-30 (Pubitemid 41095110)
99. Maindrault-Goebel F, Louvet C, Andre T et al (1999) Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). GERCOR. Eur J Cancer 35:1338-1342 (Pubitemid 29397433)
100. Andre T, Louvet C, Maindrault-Goebel F et al (1999) CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuousinfusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. GERCOR. Eur J Cancer 35:1343-1347 (Pubitemid 29397434)
101. Douillard JY, Cunningham D, Roth AD et al (2000) Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355:1041-1047 (Pubitemid 30162806)
102. Cassidy J, Clarke S, Diaz-Rubio E et al (2008) Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol 26:2006-2012
103. Diaz-Rubio E, Tabernero J, Gomez-Espana A et al (2007) Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial. J Clin Oncol 25:4224-4230 (Pubitemid 47548562)
104. Porschen R, Arkenau HT, Kubicka S et al (2007) Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group. J Clin Oncol 25:4217-4223 (Pubitemid 47548561)
105. Cunningham D, Pyrhonen S, James RD et al (1998) Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 352:1413-1418 (Pubitemid 28510874)
106. Rougier P, Van Cutsem E, Bajetta E et al (1998) Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 352:1407-1412 (Pubitemid 28510873)
107. de Gramont A, Bosset JF, Milan C et al (1997) Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol 15:808-815 (Pubitemid 27074252)
108. Jager E, Heike M, Bernhard H et al (1996) Weekly high-dose leucovorin versus low-dose leucovorin combined with fluorouracil in advanced colorectal cancer: results of a randomized multicenter trial. Study Group for Palliative Treatment of Metastatic Colorectal Cancer Study Protocol 1. J Clin Oncol 14:2274-2279 (Pubitemid 26264878)
109. Van Cutsem E, Twelves C, Cassidy J et al (2001) Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 19:4097-4106 (Pubitemid 33049527)
110. Van Cutsem E, Hoff PM, Harper P et al (2004) Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials. Br J Cancer 90:1190-1197 (Pubitemid 38496812)
111. Tournigand C, Cervantes A, Figer A et al (2006) OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer - a GERCOR study. J Clin Oncol 24:394-400 (Pubitemid 46630458)
112. Chibaudel B, Maindrault-Goebel F, Lledo G et al (2009) Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study. J Clin Oncol 27:5727-5733
113. Fuchs CS, Marshall J, Mitchell E et al (2007) Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol 25:4779-4786 (Pubitemid 350086481)
114. Hochster HS, Hart LL, Ramanathan RK et al (2008) Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study. J Clin Oncol 26:3523-3529
115. Hurwitz H, Fehrenbacher L, Novotny W et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342 (Pubitemid 38702844)
116. Kabbinavar FF, Schulz J, McCleod M et al (2005) Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 23:3697-3705
117. Kabbinavar FF, Hambleton J, Mass RD et al (2005) Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 23:3706-3712
118. Sobrero A, Ackland S, Carrion RP et al (2006) Efficacy and safety of bevacizumab in combination with irinotecan and infusional 5-FU as first-line treatment for patients with metastatic colorectal cancer. J Clin Oncol 24:3544
119. Giantonio BJ, Catalano PJ, Meropol NJ et al (2007) Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25:1539-1544 (Pubitemid 46733080)
120. Kozloff M, Yood MU, Berlin J et al (2009) Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study. Oncologist 14:862-870
121. Sugrue M, Kozloff M, Hainsworth J et al (2006) Risk factors for gastrointestinal perforations in patients with metastatic colorectal cancer receiving bevacizumab plus chemotherapy. J Clin Oncol 24:3535
122. Scappaticci FA, Skillings JR, Holden SN et al (2007) Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 99:1232-1239 (Pubitemid 47299901)
123. Cassidy J, Cunningham D, Berry SR et al (2008) Survey with curative intent in patients (pts) treated with first-line chemotherapy (CT)+bevacizumab(BEV) for metastatic colorectal cancer (mCRC): First BEAT and NO16966. J Clin Oncol 26:4022
124. Scappaticci FA, Fehrenbacher L, Cartwright T et al (2005) Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol 91:173-180 (Pubitemid 41254420)
125. Cunningham D, Humblet Y, Siena S et al (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337-345 (Pubitemid 38944402)
126. Saltz LB, Meropol NJ, Loehrer PJ Sr et al (2004) Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 22:1201-1208 (Pubitemid 41079832)
127. Saltz LB, Lenz HJ, Kindler HL et al (2007) Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study. J Clin Oncol 25:4557-4561 (Pubitemid 350035312)
128. Karapetis CS, Khambata-Ford S, Jonker DJ et al (2008) K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359:1757-1765
129. Sobrero AF, Maurel J, Fehrenbacher L et al (2008) EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 26:2311-2319
130. Bokemeyer C, Bondarenko I, Hartmann JT et al (2010) Biomarkers predictive for outcome in patients with metastatic colorectal cancer (mCRC) treated with first-line FOLFOX4 plus or minus cetuximab: updated data from the OPUS study. Proceedings of American Society of Clinical Oncology (ASCO) Gastrointestinal Cancer Symposium, January 22, Orlando, USA. American Society of Clinical Oncology (ASCO)
131. Van Cutsem E, Lang I, Folprecht G et al (2010) Cetuximab plus FOLFIRI in the treatment of metastatic colorectal cancer (mCRC): the influence of KRAS AND BRAF biomarkers on outcome: updated data from the CRYSTAL trial. Proceedings of American Society of Clinical Oncology (ASCO) Gastrointestinal Cancer Symposium, January 22, Orlando, USA. American Society of Clinical Oncology (ASCO)
132. Kohne C, Rougier P, Stroh C et al (2010) Cetuximab with chemotherapy (CT) as first-line treatment for metastatic colorectal cancer (mCRC): a meta-analysis of the CRYSTAL and OPUS studies according to KRAS and BRAF mutation status. Proceedings of American Society of Clinical Oncology (ASCO) Gastrointestinal Cancer Symposium, January 22, Orlando, USA. American Society of Clinical Oncology (ASCO)
133. Van Cutsem E, Peeters M, Siena S et al (2007) Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapyrefractory metastatic colorectal cancer. J Clin Oncol 25:1658-1664 (Pubitemid 46797944)
134. Peeters M, Price TJ, Cervantes A et al (2010) Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as secondline treatment in patients with metastatic colorectal cancer. J Clin Oncol 28:4706-4713
135. Hecht JR, Mitchell E, Chidiac T et al (2009) A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol 27:672-680
136. Tol J, Koopman M, Cats A et al (2009) Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 360:563-572
137. Sugarbaker PH (1996) Observations concerning cancer spread within the peritoneal cavity and concepts supporting an ordered pathophysiology. Cancer Treat Res 82:79-100
138. Koppe MJ, Boerman OC, Oyen WJ, Bleichrodt RP (2006) Peritoneal carcinomatosis of colorectal origin: incidence and current treatment strategies. Ann Surg 243:212-222 (Pubitemid 43185440)
139. Guller U, Zajac P, Schnider A et al (2002) Disseminated single tumor cells as detected by realtime quantitative polymerase chain reaction represent a prognostic factor in patients undergoing surgery for colorectal cancer. Ann Surg 236:768-775
140. Wind P, Norklinger B, Roger V et al (1999) Long-term prognostic value of positive peritoneal washing in colon cancer. Scand J Gastroenterol 34:606-610 (Pubitemid 29339215)
141. Archer AG, Sugarbaker PH, Jelinek JS (1996) Radiology of peritoneal carcinomatosis. Cancer Treat Res 82:263-288
142. Fong Y, Saldinger PF, Akhurst T et al (1999) Utility of 18F-FDG positron emission tomography scanning on selection of patients for resection of hepatic colorectal metastases. Am J Surg 178(4):282-7
143. Chu DZ, Lang NP, Thompson C et al (1989) Peritoneal carcinomatosis in nongynecologic malignancy. A prospective study of prognostic factors. Cancer 63:364-367
144. Jayne DG, Fook S, Loi C, Seow-Choen F (2002) Peritoneal carcinomatosis from colorectal cancer. Br J Surg 89:1545-1550 (Pubitemid 35404323)
145. Sadeghi B, Arvieux C, Glehen O et al (2000) Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer 88:358-363 (Pubitemid 30051820)
146. Verwaal VJ, van Ruth S, de Bree E et al (2003) Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 21:3737-3743 (Pubitemid 46606227)
147. Carmignani CP, Ortega-Perez G, Sugarbaker PH (2004) The management of synchronous peritoneal carcinomatosis and hematogenous metastasis from colorectal cancer. Eur J Surg Oncol 30:391-398 (Pubitemid 38528923)
148. Culliford AT, Brooks AD, Sharma S et al (2001) Surgical debulking and intraperitoneal chemotherapy for established peritoneal metastases from colon and appendix cancer. Ann Surg Oncol 8:787-795 (Pubitemid 34003327)
149. Elias D, Pocard M, Sideris L et al (2004) Preliminary results of intraperitoneal chemohyperthermia with oxaliplatin in peritoneal carcinomatosis of colorectal origin. Br J Surg 91:455-456 (Pubitemid 38491115)
150. Elias D, Delperro JR, Sideris L et al (2004) Treatment of peritoneal carcinomatosis from colorectal cancer: impact of complete cytoreductive surgery and difficulties in conducting randomized trials. Ann Surg Oncol 11:518-521 (Pubitemid 40486734)
151. Glehen O, Cotte E, Schreiber V et al (2004) Intraperitoneal chemohyperthermia and attempted cytoreductive surgery in patients with peritoneal carcinomatosis of colorectal origin. Br J Surg 91:747-754 (Pubitemid 38746144)
152. Glehen O, Kwiatkowski F, Sugarbaker PH et al (2004) Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol 22:3284-3292 (Pubitemid 41103684)
153. Jacquet P, Stephens AD, Averbach AM et al (1996) Analysis of morbidity and mortality in 60 patients with peritoneal carcinomatosis treated by cytoreductive surgery and heated intraoperative intraperitoneal chemotherapy. Cancer 77:2622-2629
154. Kecmanovic DM, Pavlov MJ, Ceranic MS et al (2005) Treatment of peritoneal carcinomatosis from colorectal cancer by cytoreductive surgery and hyperthermic perioperative intraperitoneal chemotherapy. Eur J Surg Oncol 31:147-152 (Pubitemid 40214749)
155. Mahteme H, Hansson J, Berglund A et al (2004) Improved survival in patients with peritoneal metastases from colorectal cancer: a preliminary study. Br J Cancer 90:403-407 (Pubitemid 38250636)
156. Pilati P, Mocellin S, Rossi CR et al (2003) Cytoreductive surgery combined with hyperthermic intraperitoneal intraoperative chemotherapy for peritoneal carcinomatosis arising from colon adenocarcinoma. Ann Surg Oncol 10:508-513 (Pubitemid 40486913)
157. Schneebaum S, Arnold MW, Staubus A et al (1996) Intraperitoneal hyperthermic perfusion with mitomycin C for colorectal cancer with peritoneal metastases. Ann Surg Oncol 3:44-50 (Pubitemid 126729488)
158. Shen P, Hawksworth J, Lovato J et al (2004) Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy with mitomycin C for peritoneal carcinomatosis from nonappendiceal colorectal carcinoma. Ann Surg Oncol 11:178-186 (Pubitemid 40486793)
159. Sugarbaker PH, Jablonski KA (1995) Prognostic features of 51 colorectal and 130 appendiceal cancer patients with peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemotherapy. Ann Surg 221:124-132
160. Sugarbaker PH, Schellinx ME, Chang D et al (1996) Peritoneal carcinomatosis from adenocarcinoma of the colon. World J Surg 20:585-591
161. Verwaal VJ, van Tinteren H, van Ruth S, Zoetmulder FA (2004) Predicting the survival of patients with peritoneal carcinomatosis of colorectal origin treated by aggressive cytoreduction and hyperthermic intraperitoneal chemotherapy. Br J Surg 91:739-746 (Pubitemid 38746143)
162. Verwaal VJ, Boot H, Aleman BM et al (2004) Recurrences after peritoneal carcinomatosis of colorectal origin treated by cytoreduction and hyperthermic intraperitoneal chemotherapy: location, treatment, and outcome. Ann Surg Oncol 11:375-379 (Pubitemid 40486746)
163. Verwaal VJ, Zoetmulder FA (2004) Follow-up of patients treated by cytoreduction and chemotherapy for peritoneal carcinomatosis of colorectal origin. Eur J Surg Oncol 30:280-285 (Pubitemid 38425645)
164. Verwaal VJ, van Tinteren H, Ruth SV, Zoetmulder FA (2004) Toxicity of cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy. J Surg Oncol 85:61-67 (Pubitemid 38160772)
165. Witkamp AJ, de Bree E, Kaag MM et al (2001) Extensive cytoreductive surgery followed by intraoperative hyperthermic intraperitoneal chemotherapy with mitomycin-C in patients with peritoneal carcinomatosis of colorectal origin. Eur J Cancer 37:979-984 (Pubitemid 32397682)
166. Jacquet P, Sugarbaker PH (1996) Clinical research methodologies in diagnosis and staging of patients with carcinomatosis. In: Sugarbaker PH (ed.) Peritoneal carcinomatosis: principles of management. Kluwer Academic, Boston, pp 359-374
167. Elias D, Lefevre JH, Chevalier J et al (2009) Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol 27:681-685
168. van Leeuwen BL, Graf W, Pahlman L, Mahteme H (2008) Swedish experience with peritonectomy and HIPEC. HIPEC in peritoneal carcinomatosis. Ann Surg Oncol 15:745-753
169. Yan TD, Bijelic L, Sugarbaker PH (2007) Critical analysis of treatment failure after complete cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal dissemination from appendiceal mucinous neoplasms. Ann Surg Oncol 14:2289-2299 (Pubitemid 47174931)
170. Elias D, Gilly F, Boutitie F et al (2010) Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol 28:63-68
171. Bijelic L, Yan TD, Sugarbaker PH (2007) Failure analysis of recurrent disease following complete cytoreduction and perioperative intraperitoneal chemotherapy in patients with peritoneal carcinomatosis from colorectal cancer. Ann Surg Oncol 14:2281-2288 (Pubitemid 47174917)
172. Esquivel J, Sticca R, Sugarbaker P et al (2007) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin: a consensus statement. Society of Surgical Oncology. Ann Surg Oncol 14:128-133 (Pubitemid 44954279)
173. Yan TD, Black D, Savady R, Sugarbaker PH (2006) Systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal carcinoma. J Clin Oncol 24:4011-4019 (Pubitemid 46630752)
174. Kianmanesh R, Scaringi S, Sabate JM et al (2007) Iterative cytoreductive surgery associated with hyperthermic intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis of colorectal origin with or without liver metastases. Ann Surg 245:597-603 (Pubitemid 46555664)
175. Temple LK, Hsieh L, Wong WD et al (2004) Use of surgery among elderly patients with stage IV colorectal cancer. J Clin Oncol 22:3475-3484 (Pubitemid 41103653)
176. Poultsides GA, Servais EL, Saltz LB et al (2009) Outcome of primary tumor in patients with synchronous stage IV colorectal cancer receiving combination chemotherapy without surgery as initial treatment. J Clin Oncol 27:3379-3384
177. Baron TH, Dean PA, Yates MR III et al (1998) Expandable metal stents for the treatment of colonic obstruction: techniques and outcomes. Gastrointest Endosc 47:277-286 (Pubitemid 28155352)
178. Camunez F, Echenagusia A, Simo G et al (2000) Malignant colorectal obstruction treated by means of self-expanding metallic stents: effectiveness before surgery and in palliation. Radiology 216:492-497 (Pubitemid 30599872)
179. Repici A, Reggio D, De Angelis C et al (2000) Covered metal stents for management of inoperable malignant colorectal strictures. Gastrointest Endosc 52:735-740
180. de Santibanes E, Lassalle FB, McCormack L et al (2002) Simultaneous colorectal and hepatic resections for colorectal cancer: postoperative and longterm outcomes. J Am Coll Surg 195:196-202 (Pubitemid 34832679)
181. Lyass S, Zamir G, Matot I et al (2001) Combined colon and hepatic resection for synchronous colorectal liver metastases. J Surg Oncol 78:17-21
182. Weber JC, Bachellier P, Oussoultzoglou E, Jaeck D (2003) Simultaneous resection of colorectal primary tumour and synchronous liver metastases. Br J Surg 90:956-962 (Pubitemid 37026324)
183. Tanaka K, Shimada H, Matsuo K et al (2004) Outcome after simultaneous colorectal and hepatic resection for colorectal cancer with synchronous metastases. Surgery 136:650-659 (Pubitemid 39186580)
184. Nordlinger B, Quilichini MA, Parc R et al (1987) Hepatic resection for colorectal liver metastases. Influence on survival of preoperative factors and surgery for recurrences in 80 patients. Ann Surg 205:256-263
185. Elias D, Detroz B, Lasser P et al (1995) Is simultaneous hepatectomy and intestinal anastomosis safe? Am J Surg 169:254-260
186. Lambert LA, Colacchio TA, Barth RJ (2000) Interval hepatic resection of colorectal metastases improves patient selection. Curr Surg 57:504
187. Capussotti L, Ferrero A, Vigano L et al (2007) Major liver resections synchronous with colorectal surgery. Ann Surg Oncol 14:195-201 (Pubitemid 44954289)
188. Martin R, Paty P, Fong Y et al (2003) Simultaneous liver and colorectal resections are safe for synchronous colorectal liver metastasis. J Am Coll Surg 197:233-241
189. Adam R, Delvart V, Pascal G et al (2004) Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg 240:644-657
190. Mentha G, Majno PE, Andres A et al (2006) Neoadjuvant chemotherapy and resection of advanced synchronous liver metastases before treatment of the colorectal primary. Br J Surg 93:872-878 (Pubitemid 44035261)